Victory Capital Management
AKCA

Victory Capital Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Victory Capital Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,448
Closed -$36K – 3661
2020
Q1 		$36K Buy
+2,448
New +$40.2K ﹤0.01% 2903
2019
Q4 		– Sell
-668
Closed -$10K – 3637
2019
Q3 		$10K Buy
+668
New +$14.2K ﹤0.01% 3286

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Victory Capital Management's AKCA Position: Q2 2020 in Review

Victory Capital Management sold out of Akcea Therapeutics Inc (AKCA) in Q2 2020, closing a stake of 2,448 shares — an estimated $36K sold.

Victory Capital Management first reported a position in AKCA in Q3 2019 and held it in 2 quarters. The position peaked at $36K in Q1 2020. 84 funds tracked by Wall St. Rank hold AKCA as of Q2 2020.

  • Victory Capital Management reported no remaining Akcea Therapeutics Inc position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 2,448 Akcea Therapeutics Inc shares in Q2 2020, an estimated $36K.
  • Victory Capital Management first reported a position in Akcea Therapeutics Inc in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Akcea Therapeutics Inc position peaked at $36K in Q1 2020.
  • 84 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.